RegeneRx Updates Web Site.
BETHESDA, Md. -- RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) announced today that it has updated its website at www.regenerx.com. In addition to updated historical and graphical information, the new site is easier to navigate and includes new content pertaining to the Company's technology
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43-amino acid peptide, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore RegeneRx is developing TB4 as a therapeutic platform. RegeneRx holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, and septic shock. RegeneRx is currently sponsoring three Phase II chronic dermal wound healing clinical trials and has additionally targeted ophthalmic and cardiac trials in 2006 as part of its ongoing clinical development program.
Safe Harbor Statement
The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development of TB4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.
For more information please visit RegeneRx's web site at www.regenerx.com.
In addition, make sure to read these articles:
- Healthnostics Inc. Featured by NoHype Media.
- RegeneRx Biopharmaceuticals, Inc. to Provide Update on Clinical Trials Program.
- RegeneRx Completes Short Term Debt Offering.
- RegeneRx CEO Interviewed on CEOcast.
- RegeneRx's TB4 Reduces Lethality and Decreases Inflammatory Mediators in Endotoxin-Induced...
- RegeneRx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year End 2006 Earnings...
- RegeneRx Reports 2003 Year-End Results.
- RegeneRx Holds 2003 Annual Stockholder's Meeting.
- RegeneRx Reports 2002 Year-End Results.
- RegeneRx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year End Earnings Release...
- RegeneRx Rings the AMEX Opening Bell.
- Researchers Report Thymosin Beta 4 Levels in Human Tears Decrease with Age; Four Studies...
- RegeneRx Completes $5.86 Million Private Placement.
Email
Digg It
del.icio.us
Related Resources
Business Resources
Sponsored Links
Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy
Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.
© COPYRIGHT 2006 Business Wire
You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.
Online Business Database | Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists
AllBusiness.com, its parent company D&B, and its affiliates.
